We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
Samsung Peptide AG publishes offer prospectus for public tender offer for PolyPeptide Group AG
31 Aug 2026 - Baar, 31 August 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced that Samsung Peptide AG, a […]
Read morePolyPeptide delivers +42% growth in H1 2026 and improved EBITDA margin; 2026 full-year guidance updated, now expecting 25-30% revenue growth and high-teens EBITDA margin
13 Aug 2026 - Baar, 13 August 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its H1 2026 results, updated […]
Read moreSamsung Biologics announces tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share
20 Jul 2026 - Baar, 20 July 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced Samsung Biologics’ tender offer to […]
Read morePolyPeptide Group AG takes note of market rumors and speculation
14 Apr 2026 - Baar, 14 April 2026 – PolyPeptide Group AG (SIX: PPGN) (“PolyPeptide” or the “Company”), a specialized global CDMO for peptide-based active pharmaceutical ingredients, takes note of […]
Read morePolyPeptide announces results of the annual General Meeting 2026
8 Apr 2026 - Baar, 8 April 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced that the shareholders approved all […]
Read morePolyPeptide strengthens financing structure through expansion of existing credit facility
19 Mar 2026 - Baar, 19 March 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced the strengthening of its financing structure through the expansion of its existing credit facility. PolyPeptide has expanded its existing […]
Read morePolyPeptide publishes invitation to the annual General Meeting 2026
17 Mar 2026 - Baar, 17 March 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, published today the invitation to the fifth […]
Read morePolyPeptide delivers strong revenue growth and marked improvement in profitability
12 Mar 2026 - Baar, 12 March 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its annual results for 2025 […]
Read morePolyPeptide successfully closes financial year 2025 with strong revenue growth and marked improvement in profitability
19 Jan 2026 - Baar, 19 January 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced the successful closing of its […]
Read more